Compare Nuscale Power Corporation (SMR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Nuscale Power Corporation trades at $8.26 (market cap $2.76B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6.3× Nuscale Power Corporation's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| SMR | ZBH | |
|---|---|---|
Market Cap | $2.76B | $17.36B |
Sector | Utilities | Health |
52-Week High | $53.43 | $107.71 |
52-Week Low | $7.64 | $79.58 |
Enterprise Value | $1.87B | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR (NuScale Power) trades at $7.96, up 3.2% today but remains in a bearish technical trend. The company faces severe financial strain with a net income margin of -2,066.55% and negative cash flow from operations of $459.61M in 2025. Recent earnings misses and high cash burn highlight execution risks, yet analyst consensus suggests 54% upside to a $12.25 price target, with 50% of coverage rating the stock a Buy amid optimism for its small modular reactor technology.
The stock presents a high-risk, high-reward opportunity. Long-term potential hinges on commercializing its nuclear technology, but near-term risks include persistent losses, funding needs, and project delays. Investors must weigh the speculative growth narrative against fundamental weaknesses and high volatility.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
